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women who choose to deliver at home relative to women
who choose to deliver in hospital. This study has wider im-
plications in demonstrating the application of a technique
that can be used to ascertain the utility or value attached
to attributes or characteristics associated with the process
of health care.
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BACKGROUND: During 98 several strategies have been
implemented to increase the prescription of efficient (ED)
and generic (GD) drugs. In Catalonia to improve the ge-
nerics’ use, economic incentives have been offered to some
Primary Care Teams. Although the general practitioners
(GP) in our study were not included in this incentive’s
project, they received the intervention presented in this
study.
OBJECTIVE: To evaluate an intervention to implement
ED and GD in a Primary Care District in Barcelona. 
METHODS Type of study: Pre-post intervention with con-
trol group. Setting and period: Drug prescription follow up
of the primary care district (296.000 inhabitants) and Cata-
lonia (control group) during 97, 98 and January-March 99.
Information source: Catalan Institut of Health’s pharma-
ceutical computerised system. Intervention: Design of a
sheet of paper with information about 1) prices of different
drugs for a same active principle, including those drugs re-
sponsible for higher pharmaceutical cost and with ED 2) all
generic drugs on the market and how to prescribe them. In
January 98, it was distributed to all GP. Variables: Number
and price of the drugs of 18 active principle and savings ob-
tained.
RESULTS: The savings obtained prescribing ED of ome-
prazole, enalapril and nimodipino during the period 99–
97 have increased a 182% in the district versus 103% in
Catalonia. The % of GD is also greater in our district:
Ranitidina 24% vs. 14%, Captopril 13,2% vs. 8,6%, Aci-
clovir 14,8% vs. 11.8%; Alprazolam 8.2% vs. 5% Fluox-
etina 3,73% vs. 2,7%. During January-March 99, our dis-
trict saved 69 millions (pesetas), 90% by prescribing ED
and 10% by generics.
CONCLUSION: The GP collaboration and an instrument
with updated information and easy to use have allowed to
achieve a higher percentage of ED and GD prescription in
our district. To rationalise drug’s prescription, it is neces-
sary to take into account the ED.
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OBJECTIVES: Over the last 15 years pharmacoeconom-
ics research has grown rapidly, but little is known about
the actual use of economic information by health-care de-
cision-makers. We conducted a literature review of pa-
pers addressing the use of economic information in drug
selection for hospital formularies to determine its role in
decision-making, the barriers that prevent its use and the
importance of these barriers.
METHODS: Five bibliographic databases were searched:
(1) Medline (2) Embase (3) Pascal (4) NHS Economic
Evaluation Database, and (5) International Pharmaceuti-
cal Abstracts, from 1991 to 1998. In addition a manual
search of the journal PharmacoEconomics and of the ref-
erence sections of all retrieved papers was performed. To
appraise and summarise the publications we used a 7-
point checklist.
RESULTS: We assessed 34 papers. Case studies based on
personal observations were reported in 27 (79%) papers,
surveys in 5 (15%) and literature reviews in 2 (6%). In-
put that were reported to have a greater impact on deci-
sions than economic information were: (1) the efficacy
and safety of drugs (mentioned in 100% of the papers)
(2) dosage and administration procedures (50%) (3)
quality of life considerations (32%), and (4) clinical ex-
perience of practitioners (29%). The most important of
the seven identified barriers to the use of economic infor-
mation in decision-making were: (1) lack of credibility of
economic evaluations (65%) (2) economic data did not
apply to the setting of the decision-makers (62%) (3) de-
cision-makers had no expertise in appraising economic
information (59%) (4) decision-makers did not have eco-
nomic information and it was not possible to collect it
(47%), and (5) lack of collaboration between producers
of economic information and decision-makers (41%).
CONCLUSIONS: The current use of economic informa-
tion is limited compared with its potential use. More re-
search is needed to determine decision-maker’s needs for
economic information and to identify incentives to take
this into account.
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OBJECTIVES: To assess the practicality of routine mea-
surement of patients’ quality of life during an outpatient
palliative care clinic.
METHOD: The study was a prospective evaluation of
palliative care services provided at an outpatient clinic at
Velindre NHS Trust, Cardiff. During a one-year period of
the study, patients’ self-report of quality of life was imple-
mented into the routine care. Each patient was asked to
complete the revised McGill Quality of Life Questionnaire
(MQOL) in the waiting room pre-consultation. After each
consultation, doctors recorded their comments on the pa-
